Publication date: Jul 03, 2024
Cardioneuroablation is a novel approach to treat patients with recurrent vasovagal syncope (VVS), targeting the ganglionated plexi around the atria and thus reducing the vagal input to the heart. This study reports a case of drug-refractory VVS after COVID-19 infection, successfully managed with cardioneuroablation.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Cardioneuroablation | cardioinhibitory |
| Covid | cardioneuroablation |
| Drug | COVID-19 |
| Refractoryvasovagal | syncope |
| Successfully | vasovagal |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Syncope |
| disease | MESH | COVID-19 |
| disease | MESH | Infection |
| disease | MESH | vasovagal syncope |
Original Article
(Visited 1 times, 1 visits today)